Top

Archives of Gynecology and Obstetrics

Published in:

01-07-2013 | Gynecologic Oncology

Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?

Authors: Amal Z. Azzam, Doaa I. Hashad, Nahla A. F. Kamel

Published in: Archives of Gynecology and Obstetrics | Issue 1/2013

Abstract

Purpose

To evaluate human epididymis protein 4 (HE4) as an extrabiomarker to cancer antigen 125 (CA125) to improve the detection of ovarian carcinoma.

Methods

Sixty patients with ovarian carcinoma, 50 patients with benign ovarian tumors and 30 healthy women were included in the present study. Serum concentration of HE4 was assayed using ELISA technique, while CA125 was assayed using chemiluminescent enzyme immunoassay.

Results

The median CA125 and HE4 serum values were significantly higher among ovarian cancer patients when compared with healthy control However, the median serum levels of CA125 but not HE4 were significantly higher among patients with benign ovarian tumors as compared to healthy women. Based on the receiver operator characteristics curve analysis, HE4 had higher sensitivities than CA125 for the detection of ovarian cancer at 90, 95 and 98 % specificities and the combination of both markers yielded a higher sensitivity than either alone. However, CA125 but not HE4 had higher sensitivities for the detection of benign ovarian tumors at the same specificities. In addition, a positive correlation was observed between HE4 and CA125 among patients with ovarian carcinoma.

Conclusion

HE4 is a valuable marker for ovarian cancer diagnosis and when combined with CA125, they had a higher sensitivity at a set specificity, thus providing a more accurate predictor of ovarian cancer than either alone.

Moore R, Brown A, Miller M et al (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108:402–408PubMedCrossRef

Escudero J, Auge J, Filella X et al (2011) Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and non malignant diseases. Clin Chem 57:1534–1544PubMedCrossRef

Suh K, Park S, Castro A et al (2010) Ovarian cancer biomarkers for molecular biosensors and translation medicine. Expert Rev Mol Diag 10:1069–1083CrossRef

Hartge P, Whittemore S, Itnyre J et al (1994) Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol 84(5):760–764PubMed

Kumar V, Fausto N, Abbas A (2005) Robbins & Cotran Pathologic basis of diseases, 7th edn. Saunders, Philadelphia

Banks E (2000) The epidemiology of ovarian cancer. In: Bartlett JMS (ed) Ovarian cancer: methods and protocols. Humana Press, Totowa

Bast RC (2003) Status of tumor markers in ovarian cancer screening. J Clin Oncol 21(10):200S–205SPubMedCrossRef

Jemal A, Siegel R, Ward E et al (2009) Cancer statistics 2009. CA Cancer J Clin 59:225–249PubMedCrossRef

Heitz A, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. Int J Gynecol Obstet 95:S161–S192CrossRef

10.

Huhtinen K, Suvitie P, Hissa J et al (2009) Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts. Br J Cancer 100:1315–1319PubMedCrossRef

11.

Rosen D, Atkinson J, Yu Y et al (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99:267–277PubMedCrossRef

12.

Sturgeon C, Duffy M, Stenman U et al (2008) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancer. Clin Chem 54:e11–e79PubMedCrossRef

13.

How S, Liam C, Jamalludin A (2006) Serum cancer antigen 125 in patients with pleural effusions. Med J Malaysia 61:558–563PubMed

14.

Havrilesky L, Whitehead C, Rubatt J et al (2008) Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrences. Gynecol Oncol 110:374–382PubMedCrossRef

15.

Gao L, Cheng GHY, Dong L et al (2011) The role of HE4 in ovarian cancer: inhibiting tumor cell proliferation and metastasis. J Int Med Res 39:1645–1660PubMedCrossRef

16.

Drapkin R, Von-Horsten HH, Lin Y et al (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometroid ovarian carcinomas. Cancer Res 65:2162–2169PubMedCrossRef

17.

Chen L (ed) (2010) Diagnostic Gynecologic and Obstetric Pathology, 2nd edn. : People’s Military Medical Press, Beijing, pp 268-394

18.

Kaku T, Ogawa S, Kawano Y et al (2003) Histological classification of ovarian cancer. Med Electron Microsc 36:9–17PubMedCrossRef

19.

Benedet JL, Bender H, Jones H et al (2000) FIGO staging classification and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on Gynecologic Oncology. Int J Gynecol Obstet 70:209–262CrossRef

20.

Terry K, Skates S, Mok S et al (2004) Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 20:53–70PubMed

21.

Dutta S, Wang F, Fishman D (2010) The dire need to develop a clinically validated screening method for the detection of early stage ovarian cancer. Biomark Med 4:437–439PubMedCrossRef

22.

Badgwell D, Bast R (2007) Early detection of ovarian cancer. Dis Markers 23(5–6):397–410PubMed

23.

Moore R, Mc-Meekin D, Brown A et al (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40–46PubMedCrossRef

24.

Molina R, Filella X, Bruix J et al (1991) Cancer antigen 125 in serum and ascitic fluid for patients with liver disease. Clin Chem 37:1379–1383PubMed

25.

Nolen B, Velikokhatnaya L, Marrangoni A et al (2010) Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 117:440–445PubMedCrossRef

26.

Moore R, Brown A, Miller M et al (2008) Utility of a novel serum tumor biomarker HE4 in patients with endometroid adenocarcinoma of the uterus. Gynecol Oncol 110:196–201PubMedCrossRef

27.

Yamashita S, Heagerty K, Hashimoto T et al (2011) Prognostic significance of HE4 in pulmonary adenocarcinoma. Tumor boil 32:265–271CrossRef

28.

Montagnana M, Lippi G, Ruzzenete O et al (2009) The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 23:331–335PubMedCrossRef

29.

Hellstrom I, Raycraft J, Hayden-ledbetter M et al (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63:3695–3760PubMed

30.

Hellstrom I, Hellstrom K (2008) SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol 622:15–21PubMedCrossRef

31.

Ayhan A, Guven S, Guven E et al (2007) Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand 86:484–490PubMedCrossRef

32.

Yin B, Lloyd K (2001) Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276:27371–27375PubMedCrossRef

33.

Abdel-Azeez H, Labib H, Sharaf S et al (2010) HE4 and mesothelin: novel biomarker of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 11(1):111–116PubMed

Title: Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?
Authors: Amal Z. Azzam
Doaa I. Hashad
Nahla A. F. Kamel
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 1/2013
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-013-2722-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

Erratum to: Systematic use of carbetocin during cesarean delivery of multiple pregnancies: a before-and-after study

Haplotype analysis of single nucleotide polymorphisms in anti-Müllerian hormone gene in Chinese PCOS women

Heart disease in pregnancy: cardiac and obstetric outcomes

Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects

Influence of reactive oxygen species on human sperm functions and fertilizing capacity including therapeutical approaches

Evaluation of novel serum biomarkers and the proteomic differences of endometriosis and adenomyosis using MALDI-TOF–MS